Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

NCT07717411 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07717411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07717411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Recruiting
Start date
November 30, 2026
Completion date
September 3, 2032
Enrollment
1,600 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease